BU-NOT-SET

CONTACT US
FMD: industry thoughts as serialisation deadline nears
  • Manufacturing
Eyes
Insight
Sustainability report 2019
  • Sustainability
Report
Report
Sweden’s strong contract services market
  • Drug product
  • Drug substance
Eyes
Insight
Abuse deterrent formulations: Preventing an opioid epidemic
  • Drug product
Eyes
Insight
Early phase know-how clears pathway to late stage success
  • Drug product
Eyes
Insight
Case study: Advancing therapeutics for myeloma
  • Drug product
Eyes
Insight
CPhI 2018 panel discussion: M&A outlook for pharma
  • Industry trends
Eyes
Insight
Contract Pharma: Recipharm and TraceLink Q&A
  • Manufacturing
Eyes
Insight
Serialisation milestone: Recipharm connects to European Hub
  • Manufacturing
Eyes
Insight
Insight
  • Analytical chemistry
The QbD approach: Key advantages in clinical and commercial phases
Report
  • Sustainability
Sustainability report 2020
Poster
  • Drug substance
Recipharm and Oncopeptides: Successful collaboration in the development of melflufen, a peptidase-potentiated alkylating agent in clinical trials
Fact sheet
  • Analytical chemistry
Recipharm Analytical Solutions™
Fact sheet
  • Analytical chemistry
Impurity identification
Fact sheet
  • Analytical chemistry
Stability studies
Fact sheet
  • Analytical chemistry
Extractables & leachables testing
Insight
  • Industry trends
Pharmaceutical mergers and acquisitions: opportunities and drivers for CDMOs
Insight
  • Industry trends
Global expansion in the CDMO field